Skip to content
All resources

Copper peptides

What Is AHK-Cu? The Copper Tripeptide, Its Chemistry and Its Thin Literature

IM

By

· 9 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. What is AHK-Cu made of?
  2. How does AHK hold copper, and how does it relate to GHK and albumin?
  3. How is AHK-Cu thought to work?
  4. What has AHK-Cu been studied for?
  5. Is AHK-Cu approved anywhere?
  6. What is AHK-Cu commonly confused with?
  7. Frequently asked questions

AHK-Cu is the tripeptide alanyl-histidyl-lysine (Ala-His-Lys, AHK) bound to a copper(II) ion. It differs from the far better-known GHK-Cu in one residue: alanine where GHK has glycine. Its published literature is very small. One PubMed-indexed study has examined AHK-Cu itself, a 2007 culture study of human hair follicles and dermal papilla cells. There are no published animal studies of the complex and no published human trials. It is not an approved drug anywhere, and it is sold mainly as a cosmetic ingredient.

A cut-away section of skin showing hair follicles rooted in the dermis
Illustration: hair follicles in skin, the tissue the one study of AHK-Cu examined.

What is AHK-Cu made of?

Three amino acids and a metal. The peptide is L-alanine, L-histidine and L-lysine, in that order, with a free amino group at the alanine end. Copper(II) is held by the peptide itself, so AHK-Cu is a coordination complex rather than a peptide mixed with a copper salt.

PropertyAHK-Cu
PeptideL-alanyl-L-histidyl-L-lysine (Ala-His-Lys, AHK)
MetalCopper(II)
Also calledAHK copper; sold by ingredient suppliers as "copper tripeptide-3"
Peptide formula and weight (PubChem, metal-free AHK)C15H26N6O4; about 354 g/mol
CAS number (PubChem)767286-83-9
Formula of the neutral complexC15H24CuN6O4; about 416 g/mol (the peptide plus copper(II), less two protons)
Evidence stageCell and organ culture only
Regulatory statusNo Health Canada, FDA or EMA authorisation as a drug; marketed as a cosmetic ingredient

One note on the identifiers. PubChem holds more than one AHK-Cu record, differing by charge and counterion (one is a hydrochloride salt), so formulas and weights quoted for "AHK-Cu" vary between sources. The figures above are for the neutral copper(II) complex under CAS 767286-83-9, the number PubChem and ingredient suppliers use. What is not in doubt is the peptide sequence.

How does AHK hold copper, and how does it relate to GHK and albumin?

This is where AHK-Cu is easiest to misdescribe, so it is worth being exact.

Copper chemists sort short peptides by where histidine sits relative to the free amino end. Gonzalez and colleagues set out the two canonical motifs: NH2-Xxx-His, typified by GHK, which binds copper(II) through three nitrogens from the peptide plus an outside ligand; and NH2-Xxx-Zzz-His, typified by Asp-Ala-His-Lys from human serum albumin, which binds it through four peptide nitrogens (PMID 29190078). The second is the ATCUN motif, with histidine in position three.

AHK has histidine in position two. By that classification it belongs with GHK, not with albumin's site. The sequences invite confusion: the N-terminus of human albumin is Asp-Ala-His-Lys, DAHK (PMID 11396981), and AHK is that sequence with the aspartate removed. But removing the first residue moves histidine from position three to position two, which turns an ATCUN-type site into a GHK-type one. AHK-Cu is not "the albumin copper site", and it is not a fragment that binds copper the way albumin does. The two canonical sites were compared directly for GHK and DAHK by Hureau and colleagues, who found that copper exchanges quickly on GHK and slowly on DAHK (PMID 21780203).

We found no published structural or binding-constant study of copper with AHK itself. Its similarity to GHK-Cu is an inference from the motif, a reasonable one, but not a measurement. The chemistry of the GHK complex is set out in What is GHK-Cu?

How is AHK-Cu thought to work?

No mechanism has been established. The only mechanistic data come from the 2007 study below, which reported changes in apoptosis-related proteins in cultured dermal papilla cells. There is no receptor, no binding study and no work on how the complex reaches or enters cells. Anything more specific than that is borrowed from GHK-Cu.

What has AHK-Cu been studied for?

AreaEvidence stageWhat exists
Human hair folliclesEx vivo organ cultureOne study: follicle elongation in culture (PMID 17703734)
Dermal papilla cellsCell cultureThe same study: proliferation and apoptosis markers
Dermal fibroblastsNone found for AHK-CuThe fibroblast literature indexed in PubMed is on GHK-Cu
AHK without copper, in a vitamin C conjugateCell cultureOne study in mouse myoblast cells (PMID 29567599)
Animals or peopleNone published—

Hair follicles and dermal papilla cells. Pyo and colleagues, at Seoul National University, kept human scalp hair follicles alive in culture and grew dermal papilla cells, the specialised fibroblasts at the base of the follicle. They reported that AHK-Cu lengthened the cultured follicles and increased papilla-cell proliferation. It raised the Bcl-2/Bax ratio and lowered cleaved caspase-3 and PARP, markers associated with programmed cell death. The fall in the number of apoptotic cells itself was not statistically significant (PMID 17703734). That is the whole of the primary AHK-Cu literature we could find. It has not been independently replicated, and organ culture cannot measure what a hair-count trial measures. How this paper came to be cited for GHK-Cu is traced in GHK-Cu and hair follicle research.

Fibroblasts. AHK-Cu is often described as a fibroblast and collagen peptide. The abstract of the 2007 paper opens by saying "the tripeptide-copper complex" stimulates dermal fibroblast proliferation and VEGF production, but it does not report fibroblast experiments with AHK-Cu, and we found no PubMed-indexed fibroblast study of AHK-Cu. The fibroblast work that does exist is on GHK-Cu: collagen synthesis in culture (PMID 3169264) and growth-factor production by normal and irradiated fibroblasts (PMID 15655171). Those are findings about a different molecule.

AHK without copper. Jung and colleagues studied a vitamin C-linked AHK conjugate, with no copper, in mouse myoblast cells and reported increased markers of bone-cell differentiation (PMID 29567599). It shows that AHK has been used as a building block. It says nothing about AHK-Cu.

Registered studies. ClinicalTrials.gov lists one study, enrolling by invitation as of late 2026, whose description names AHK-Cu among several peptides in a single multi-ingredient skin serum, alongside other agents (NCT07888595). It has no results, and its design could not attribute any finding to AHK-Cu alone.

Is AHK-Cu approved anywhere?

No. We found no authorisation from Health Canada, the FDA or the EMA for AHK-Cu as a drug for any indication. Ingredient suppliers sell it for skin-care and hair-care formulations under the name "copper tripeptide-3", but we could not confirm that name in a regulator's ingredient register, and a cosmetic listing, where one exists, permits an ingredient in a product. It does not establish that the ingredient does anything. Drug status in Canada can be checked in the Drug Product Database, and the general framework is in peptides and Canadian law.

What is AHK-Cu commonly confused with?

GHK-Cu. One residue apart, and very often treated as interchangeable. They are not. GHK occurs naturally in human plasma and has decades of cell, animal and some small human research; AHK has one culture study. A 2026 evidence-mapping review of the GHK-Cu literature argued that the field routinely blurs free GHK, GHK-Cu, GHK-derived copper peptides and other copper peptides, and should keep them apart (PMID 42797253). The same discipline applies here in both directions.

The albumin copper site. AHK is residues two to four of albumin's N-terminus, but as explained above it lacks the ATCUN arrangement that gives albumin its copper site.

"Copper tripeptide" in general. The phrase is used for GHK-Cu, for AHK-Cu and for blends. A product or paper that says "copper peptide" without a sequence does not tell you which molecule was used. How copper peptides compare with another cosmetic peptide family is covered in GHK-Cu vs Matrixyl.

A hair-loss treatment. No study has measured hair in people given AHK-Cu.

Supplied here for laboratory use: AHK-Cu. No certificate of analysis for this compound is published on this site yet. For laboratory research use only.

The findings above describe the compound in the cells and tissue studied, not any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

What does AHK stand for? The one-letter codes of its amino acids: A for alanine, H for histidine and K for lysine. "Cu" is the symbol for copper. AHK-Cu therefore names the tripeptide Ala-His-Lys with a copper(II) ion bound to it.

Is AHK-Cu just a synthetic GHK-Cu? It is a close analogue, with alanine in place of glycine, and by its histidine position it should bind copper in the same general way. But it has its own, much smaller literature, and nobody has published a direct comparison of the two. Results for GHK-Cu are not results for AHK-Cu.

How much research is there on AHK-Cu? Very little. One PubMed-indexed study examined the copper complex, in human hair follicles and dermal papilla cells in culture, in 2007. We found no animal studies, no published human trials and no structural study of the complex.

Has AHK-Cu been tested on hair in people? Not in any published trial. The only hair data are from follicles kept alive in culture. Whether a change seen in organ culture would appear as a measurable change in hair count is a question only a placebo-controlled human trial could answer; see how to read a peptide study.

Is AHK-Cu legal in Canada? It has no Canadian authorisation as a drug. It is sold here as a laboratory research chemical, not for human use.

Selected Research References

  1. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839. pubmed.ncbi.nlm.nih.gov/17703734
  2. Gonzalez P, Vileno B, Bossak K, et al. Cu(II) binding to the peptide Ala-His-His, a chimera of the canonical Cu(II)-binding motifs Xxx-His and Xxx-Zzz-His. Inorganic Chemistry. 2017;56(24):14870-14879. pubmed.ncbi.nlm.nih.gov/29190078
  3. Bar-Or D, Rael LT, Lau EP, et al. An analog of the human albumin N-terminus (Asp-Ala-His-Lys) prevents formation of copper-induced reactive oxygen species. Biochemical and Biophysical Research Communications. 2001;284(3):856-862. pubmed.ncbi.nlm.nih.gov/11396981
  4. Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry: A European Journal. 2011;17(36):10151-10160. pubmed.ncbi.nlm.nih.gov/21780203
  5. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. pubmed.ncbi.nlm.nih.gov/3169264
  6. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Archives of Facial Plastic Surgery. 2005;7(1):27-31. pubmed.ncbi.nlm.nih.gov/15655171
  7. Jung JI, Park KY, Lee Y, et al. Vitamin C-linker-conjugated tripeptide AHK stimulates BMP-2-induced osteogenic differentiation of mouse myoblast C2C12 cells. Differentiation. 2018;101:1-7. pubmed.ncbi.nlm.nih.gov/29567599
  8. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics. 2026;18(9):1077. pubmed.ncbi.nlm.nih.gov/42797253

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.